ACE 083

Drug Profile

ACE 083

Alternative Names: ACE-083

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Class Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Facioscapulohumeral muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Charcot-Marie-Tooth disease; Facioscapulohumeral muscular dystrophy
  • Discontinued Inclusion body myositis

Most Recent Events

  • 24 Jul 2018 Efficacy and adverse events data from a part I of phase II trial in Charcot-Marie-Tooth disease released by Acceleron Pharma
  • 12 Jul 2018 ACE 083 receives Orphan Drug status for Facioscapulohumeral muscular dystrophy in USA
  • 01 May 2018 ACE 083 receives Fast Track designation for Facioscapulohumeral muscular dystrophy [IM,Injection] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top